{"id":"candidate-plasmodium-falciparum-malaria-vaccine","safety":{"commonSideEffects":[{"rate":"50-70","effect":"Injection site pain or swelling"},{"rate":"15-30","effect":"Fever"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"5-15","effect":"Myalgia"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:27:21.022330","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant circumsporozoite protein (CSP) fused to hepatitis B surface antigen, combined with an AS01 adjuvant system that enhances immune response. It primes both cellular and humoral immunity against the malaria parasite, reducing parasitemia levels and clinical malaria episodes in vaccinated individuals.","oneSentence":"This vaccine stimulates the immune system to recognize and attack Plasmodium falciparum parasites, primarily targeting the parasite's pre-erythrocytic and blood-stage antigens to prevent malaria infection and disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:51.074Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plasmodium falciparum malaria prevention in endemic populations"},{"name":"Malaria prevention in children and infants in sub-Saharan Africa"}]},"_fixedFields":["pubmed(20)"],"trialDetails":[{"nctId":"NCT06735209","phase":"PHASE1","title":"First-in-Human PfSPZ-LARC2 Vaccination/CHMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-23","conditions":"Malaria","enrollment":22},{"nctId":"NCT05357560","phase":"PHASE1","title":"A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-07-10","conditions":"Malaria, Plasmodium Falciparum","enrollment":107},{"nctId":"NCT07124156","phase":"PHASE1","title":"A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate","status":"NOT_YET_RECRUITING","sponsor":"European Vaccine Initiative","startDate":"2026-03-20","conditions":"Malaria Fever","enrollment":24},{"nctId":"NCT05400746","phase":"EARLY_PHASE1","title":"A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2022-11-02","conditions":"Malaria, Plasmodium Falciparum","enrollment":17},{"nctId":"NCT03947190","phase":"PHASE2","title":"A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2022-08-31","conditions":"Malaria,Falciparum","enrollment":80},{"nctId":"NCT03281291","phase":"","title":"Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-11-19","conditions":"Malaria","enrollment":1500},{"nctId":"NCT05441410","phase":"PHASE1, PHASE2","title":"Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-06-01","conditions":"Malaria","enrollment":30},{"nctId":"NCT04318002","phase":"PHASE1","title":"Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-01-21","conditions":"Malaria,Falciparum","enrollment":60},{"nctId":"NCT05978037","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-08-18","conditions":"Malaria, Malaria,Falciparum, Parasitic Disease","enrollment":58},{"nctId":"NCT03276962","phase":"PHASE2","title":"Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-28","conditions":"Malaria","enrollment":1500},{"nctId":"NCT05644067","phase":"PHASE1","title":"Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2023-08-25","conditions":"Malaria","enrollment":40},{"nctId":"NCT02458092","phase":"PHASE1","title":"Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2008-04","conditions":"Malaria","enrollment":30},{"nctId":"NCT02927145","phase":"PHASE1, PHASE2","title":"A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-10-17","conditions":"Malaria","enrollment":88},{"nctId":"NCT02699099","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-10","conditions":"Malaria, Malaria Vaccines","enrollment":699},{"nctId":"NCT01540474","phase":"PHASE1","title":"Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2012-02","conditions":"Malaria","enrollment":36},{"nctId":"NCT00223990","phase":"PHASE2","title":"Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2005-04-08","conditions":"Malaria, Falciparum","enrollment":400},{"nctId":"NCT00289185","phase":"PHASE2","title":"Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-27","conditions":"Malaria, Malaria Vaccines","enrollment":340},{"nctId":"NCT03084289","phase":"PHASE1","title":"A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-03-28","conditions":"Malaria","enrollment":26},{"nctId":"NCT04130282","phase":"PHASE1","title":"VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2019-09-27","conditions":"Malaria,Falciparum","enrollment":1},{"nctId":"NCT02207816","phase":"PHASE3","title":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-18","conditions":"Malaria","enrollment":3084},{"nctId":"NCT00866619","phase":"PHASE3","title":"Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-27","conditions":"Malaria","enrollment":15459},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Malaria, Malaria Vaccines","enrollment":705},{"nctId":"NCT02780154","phase":"PHASE1","title":"PfSPZ Challenge in Non-immune Adults in Baltimore, USA","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-08-25","conditions":"Plasmodium Falciparum Infection","enrollment":30},{"nctId":"NCT00312702","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2006-04","conditions":"Malaria, Plasmodium Falciparum Malaria","enrollment":18},{"nctId":"NCT00312663","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2006-04","conditions":"Plasmodium Falciparum Malaria","enrollment":24},{"nctId":"NCT01323972","phase":"PHASE3","title":"Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-05-16","conditions":"Malaria","enrollment":327},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511},{"nctId":"NCT01231503","phase":"PHASE2","title":"Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-13","conditions":"Malaria","enrollment":480},{"nctId":"NCT01949909","phase":"PHASE1","title":"Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2014-03","conditions":"Malaria","enrollment":56},{"nctId":"NCT00380393","phase":"PHASE2","title":"Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-03","conditions":"Malaria","enrollment":894},{"nctId":"NCT00360230","phase":"PHASE2","title":"Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-30","conditions":"Malaria","enrollment":540},{"nctId":"NCT02174978","phase":"PHASE1","title":"Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2014-08","conditions":"Malaria","enrollment":39},{"nctId":"NCT00308061","phase":"PHASE1","title":"Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2003-07","conditions":"Malaria","enrollment":40},{"nctId":"NCT00307021","phase":"PHASE2","title":"Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-07","conditions":"Malaria","enrollment":180},{"nctId":"NCT00323622","phase":"PHASE2","title":"Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Malaria","enrollment":1737},{"nctId":"NCT02252640","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-01","conditions":"Plasmodium Falciparum Malaria","enrollment":48},{"nctId":"NCT01341704","phase":"PHASE2","title":"Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa","status":"COMPLETED","sponsor":"Vac4All","startDate":"2011-05","conditions":"Malaria","enrollment":800},{"nctId":"NCT00666380","phase":"PHASE1","title":"A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2008-04","conditions":"Malaria","enrollment":26},{"nctId":"NCT00284973","phase":"PHASE1","title":"A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate","status":"COMPLETED","sponsor":"Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.","startDate":"2006-01","conditions":"Prophylaxis Against Plasmodium Falciparum Malaria","enrollment":70},{"nctId":"NCT01883609","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2013-09","conditions":"Plasmodium Falciparum Malaria","enrollment":48},{"nctId":"NCT01556945","phase":"PHASE1, PHASE2","title":"Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2001-04","conditions":"Malaria, Falciparum","enrollment":72},{"nctId":"NCT01658696","phase":"PHASE2","title":"Efficacy of Candidate Malaria Vaccines in Senegalese Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-08","conditions":"Malaria","enrollment":120},{"nctId":"NCT01739036","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2013-01","conditions":"Plasmodium Falciparum Malaria","enrollment":48},{"nctId":"NCT00587249","phase":"PHASE1","title":"ICC-1132 - Candidate Vaccine Against P Falciparum Malaria","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-07","conditions":"Plasmodium Falciparum Malaria","enrollment":75},{"nctId":"NCT00890019","phase":"PHASE1","title":"A Study of AdCh63 ME-TRAP Alone and With MVA ME-TRAP","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-07","conditions":"Malaria","enrollment":54},{"nctId":"NCT01605786","phase":"PHASE1, PHASE2","title":"Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage)","status":"UNKNOWN","sponsor":"Vac4All","startDate":"2012-05","conditions":"Malaria","enrollment":36},{"nctId":"NCT00509158","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2007-10","conditions":"Healthy","enrollment":36},{"nctId":"NCT00652275","phase":"PHASE2","title":"Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine","status":"UNKNOWN","sponsor":"African Malaria Network Trust","startDate":"2008-05","conditions":"Malaria","enrollment":378},{"nctId":"NCT00469651","phase":"PHASE1","title":"Phase Ib Trial of MSP3 LSP in Children in Tanzania","status":"UNKNOWN","sponsor":"African Malaria Network Trust","startDate":"2007-10","conditions":"Malaria","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"recentPublications":[{"date":"2024 Oct","pmid":"38880111","title":"Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.","journal":"The Lancet. Infectious diseases"},{"date":"2024 Jun 7","pmid":"38849365","title":"Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.","journal":"Nature communications"},{"date":"2024 Mar 19","pmid":"38388238","title":"Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.","journal":"Vaccine"},{"date":"2023 Feb 15","pmid":"36851323","title":"B-Cell Epitope Mapping of the Plasmodium falciparum Malaria Vaccine Candidate GMZ2.6c in a Naturally Exposed Population of the Brazilian Amazon.","journal":"Vaccines"},{"date":"2019","pmid":"31214195","title":"Functional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens.","journal":"Frontiers in immunology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GSK Biologicals' candidate Plasmodium falciparum malaria vaccine adjuvanted with GSK Biologicals' proprietary Adjuvant System AS01E (RTS,S/AS01E)"],"phase":"phase_3","status":"active","brandName":"Candidate Plasmodium falciparum malaria vaccine","genericName":"Candidate Plasmodium falciparum malaria vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and attack Plasmodium falciparum parasites, primarily targeting the parasite's pre-erythrocytic and blood-stage antigens to prevent malaria infection and disease. Used for Plasmodium falciparum malaria prevention in endemic populations, Malaria prevention in children and infants in sub-Saharan Africa.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}